Funding for this research was provided by:
Eli Lilly and Company
Text and Data Mining valid from 2018-08-13
Received: 21 February 2018
Accepted: 9 July 2018
First Online: 13 August 2018
Ethics approval and consent to participate
: The study was performed in accordance with the principles of the Declaration of Helsinki. All investigation sites received approval from ethics committees or institutional review boards. For the SPIRIT-P1 study, the institutional review board for the primary investigator was the Western Institutional Review Board (#1–838,258-1), and for the SPIRIT-P2 study, the institutional review board for the primary investigator was the Bellberry Human Research Ethics Committee (#2015–01-049-AA). Patients provided written informed consent before any study-related procedures were undertaken.
: Not applicable.
: LCC has served on advisory boards for, and received research funding and speakers’ fees from Abbvie, Pfizer, MSD, UCB, and Celgene. PSH has served on advisory boards for and received speakers’ fees from Amgen, Abbvie, BMS, Janssen, Pfizer, MSD, UCB, and Celgene, and has received research funding from Abbvie and Pfizer. AO has served as a consultant for Eli Lilly, Janssen, Novartis, Pfizer and UCB, and has received research funding from Celgene, Eli Lilly, Horizon, Janssen, and Novartis (to Johns Hopkins University). OB, LK, DHA, CLS, and JB were employees and minor shareholders of Eli Lilly and Company or its subsidiaries.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.